Compare Ginkgo Bioworks Holdings Inc (DNA) vs First Solar, Inc. (FSLR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs First Solar, Inc. — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.32 (market cap $485.52M), while First Solar, Inc. trades at $225.44 (market cap $25.89B). The key difference: First Solar, Inc. is far larger — about 53.3× Ginkgo Bioworks Holdings Inc's market cap, and First Solar, Inc. is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| DNA | FSLR | |
|---|---|---|
Market Cap | $485.52M | $25.89B |
Sector | Health | Technology |
52-Week High | $16.14 | $318.30 |
52-Week Low | $5.48 | $180.05 |
Enterprise Value | $587.47M | $24.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.21, down 5.75% today, amid bearish technical signals and weak fundamentals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, with persistent losses and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant sell-side coverage, while technical indicators show strong bearish momentum with support at $7.
DNA faces substantial execution risks as it pivots to autonomous lab services, with negative profitability metrics and declining revenue creating headwinds. The stock's valuation appears stretched relative to fundamentals, though recent earnings beats offer some optimism. Investors should weigh the company's long-term biotech potential against near-term financial challenges.
First Solar (FSLR) trades at $228.27, down 4.62% on the day, amid mixed signals. The stock shows a bullish technical trend with strong moving averages, though RSI levels suggest potential overbought conditions. Fundamentally, the company reported robust revenue growth to $5.22B in 2025, with a net income margin of 29.27%, while recent earnings beat expectations in Q1 and Q2 2026. However, multiple class-action lawsuits filed in August 2026 create near-term legal overhang.
The outlook remains positive given analyst consensus favoring a buy rating with a $282.07 price target, implying significant upside. Key risks include legal proceedings and competitive pressures in the solar sector. Earnings growth and operational cash flow strength support long-term value, but investors should weigh legal uncertainties against fundamental strengths.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →
